AbbVie | ABBV - Cost Of Sales

Stock Price
197.69
Daily Change
0.31 0.16%
Monthly
-7.24%
Yearly
2.16%
Q2 Forecast
194.46

AbbVie reported $4.55B in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Abbott USD 5.3B 380M Mar/2026
ALKERMES USD 46.21M 5.38M Dec/2025
Amgen USD 1.79B 128M Dec/2025
AstraZeneca USD 3.27B 471M Dec/2025
Biogen USD 810.1M 205.1M Sep/2025
BioMarin Pharmaceutical USD 161.56M 16.62M Dec/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Coherus Biosciences USD 4.04M 324K Dec/2025
Eisai JPY 51.08B 5.56B Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Gilead Sciences USD 1.62B 50M Dec/2025
GlaxoSmithKline GBP 2.61B 377M Dec/2025
Infinity Pharmaceuticals USD 352K 89K Jun/2023
J&J USD 8.07B 103M Mar/2026
Medtronic USD 3.61B 83M Dec/2025
Merck USD 3.32B 531M Dec/2025
Neurocrine Biosciences USD 17.6M 246.4M Dec/2025
Novartis USD 3.54B 3M Dec/2025
Pacira USD 54.62M 6.02M Dec/2025
Perrigo USD 747.4M 81.2M Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Roche Holding CHF 8.48B 4.61B Dec/2025
Sanofi EUR 3.67B 621M Mar/2026
UCB EUR 1.07B 146M Dec/2025
Ultragenyx Pharmaceutical USD 29M 1.01M Dec/2025
United Therapeutics USD 474.7M 373.8M Dec/2025
Vertex Pharmaceuticals USD 466M 51.2M Dec/2025
Zoetis USD 743M 60M Dec/2025